Flupentixol: Mechanism of Action as an Antipsychotic

Flupentixol is the international nonproprietary name (INN) of the substance known under the trade name Fluanxol. In Germany, flupentixol is used as a tablet, liquid drops, and as a long-acting depot injection (flupentixol decanoate) for the treatment of schizophrenic psychoses and in low dosage as adjunctive therapy for depression with apathy. It belongs to the class of thioxanthene antipsychotics and has been an established active substance in psychiatry since the 1960s.

Characteristic of flupentixol is its dose-dependent effect. At low doses (0.5 to 3 mg per day), it acts predominantly as an antidepressant and activating agent. At higher doses (up to 60 mg per day), it exerts an antipsychotic effect. This property is valuable in clinical practice because the same substance can be used for different indications. The depot formulation with a duration of action of two to four weeks is an option for patients with limited adherence to oral therapy.

Mechanism of Action

Flupentixol blocks dopamine D1 and D2 receptors with pronounced affinity, as well as serotonin 5HT2A, histamine H1, and alpha 1 adrenergic receptors. Blockade of D2 receptors in mesolimbic pathways reduces positive symptoms such as delusions and hallucinations. The additional 5HT2A blockade contributes to a lower incidence of extrapyramidal motor adverse effects and can slightly improve negative and cognitive symptoms.

At low doses, predominantly presynaptic D2 receptors appear to be blocked, which paradoxically increases dopamine release and thus explains the drive-enhancing, antidepressive effect. This effect is unique among classical antipsychotics and makes flupentixol of interest in inhibited depressed patients. Off-label use in this indication is well established in Germany.

Pharmacokinetically, flupentixol shows a half-life of approximately 35 hours, allowing once or twice daily administration. Metabolism occurs predominantly hepatically via CYP2D6. Genetic variants and concomitant medication can significantly affect blood levels. The depot formulation with decanoate ester is administered intramuscularly, released slowly from muscle tissue, and has a duration of action of 2 to 4 weeks.

Indications

• Schizophrenia and schizoaffective disorder, especially in chronic courses, with oral tablet or as depot
• Depression with apathy and psychomotor retardation, at low dose (0.5 to 3 mg per day)
• Maintenance therapy following successful acute treatment, with depot to improve medication adherence
• Manic phases, in combination with mood stabilizers such as lithium
• Off-label use in aggressive behavioral disorder in specialized settings

Flupentixol is not first-line therapy for dementia-related behavioral disturbances, as antipsychotics in this patient population increase the risk of stroke and mortality. In acute mania without psychotic symptoms, mood stabilizers or atypical antipsychotics are often prioritized.

Dosage and Administration

Schizophrenia oral: Start with 1 to 5 mg two to three times daily, individual dose escalation. Maintenance dose usually 3 to 15 mg per day, up to 40 mg per day in acute phases.

Depression with apathy (off-label): 0.5 to 1 mg in the morning, if necessary increase to 1.5 to 3 mg per day. Higher doses transition into the antipsychotic range.

Depot (flupentixol decanoate): 20 to 100 mg intramuscularly every 2 to 4 weeks, individual adjustment based on clinical response. Dose escalation stepwise.

Pediatric: not approved for children.

Renal insufficiency: generally no dose adjustment required. Hepatic insufficiency: dose reduction required in moderate to severe impairment, as hepatic metabolism is dominant.

Administration: Tablets swallowed whole with water, preferably at the same time daily. Activating effect at low dose, therefore prefer morning administration to avoid sleep disturbances.

Depot administration: Injection ideally in the gluteus or deltoid muscle. Rotate injection sites. Initially overlap oral therapy during dose escalation.

Adverse Effects

Very common: Drowsiness or paradoxically sleep disturbances, fatigue, dry mouth, weight gain, orthostatic hypotension.

Common: Extrapyramidal motor symptoms such as akathisia, parkinsonism, acute dystonia, hyperprolactinemia with galactorrhea, menstrual irregularities or erectile dysfunction, tachycardia, constipation, weight gain.

Occasionally to rare: Tardive dyskinesia with long-term therapy, neuroleptic malignant syndrome (NMS) with fever, muscle rigidity, altered consciousness, and elevated CK, QT prolongation, metabolic syndrome, seizures, allergic skin reactions.

Use in dementia: Increased mortality and stroke risk in elderly demented patients, applies to the entire drug class.

Suicidality: Increased baseline risk in patients with schizophrenia and schizoaffective disorder. Close psychiatric monitoring is essential.

Drug Interactions

• Other centrally depressant substances (benzodiazepines, Z-drugs, opioids, alcohol): enhanced sedation, fall risk.
• QT-prolonging drugs (methadone, amiodarone, citalopram in higher dose, some antibiotics): cumulative QT prolongation.
• Antihypertensives: additive hypotension and fall risk.
• Levodopa and dopamine agonists: mutual reduction in effect.
• CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion): increased flupentixol levels.
• CYP2D6 inducers: lower levels, reduced efficacy.
• Lithium: rare neurotoxic symptoms with combination, clinical monitoring required.
• Anticholinergics: sometimes combined in extrapyramidal symptoms (biperiden), additive anticholinergic effect.

Special Precautions

Pregnancy: Limited data. In the third trimester, neonatal adjustment disorders with tremor, sleep disturbances, respiratory problems, or feeding difficulties are possible. Use following individual risk-benefit assessment. Breastfeeding: Transfer into breast milk, breastfeeding during therapy is generally not recommended.

Children and adolescents: Not approved.

Elderly patients: Increased sensitivity to sedation, falls, cardiac effects. Low starting dose, slow titration, ECG in patients with cardiac risk factors.

Before starting therapy: ECG with QT assessment, electrolytes, liver and kidney values, blood glucose and lipid values, if necessary pregnancy test. History of previous antipsychotics, extrapyramidal symptoms, cardiac disease, seizures.

Treatment monitoring: Regular re-evaluation of efficacy, observation of extrapyramidal symptoms, weight and metabolic monitoring every three to six months, prolactin on clinical indication.

Depot switch: When switching between oral and depot therapy, follow exact overlap schemes carefully, as onset and duration of action differ.

Lifestyle: Diet, exercise, social structuring, avoidance of drugs and excessive alcohol support treatment success.

Driving ability: Often limited during dose initiation and changes, possible in stable state following individual assessment.

You May Also Be Interested In

• Fluanxol, alternative designation for flupentixol
• Aripiprazol, partial D2 agonist with different profile
• Paliperidon, atypical antipsychotic with depot options
• Levomepromazin, sedating low-potency antipsychotic
• Dipiperon (Pipamperon), sedating antipsychotic

Frequently Asked Questions

Sources

• Gelbe Liste, Flupentixol active substance profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, S3 Guideline Schizophrenia
• German Society for Psychiatry